Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
← catalyst calendarNCT07797283 · readout in 2,068 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
590estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-01
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-12-01 | estimated | When the study began enrolling |
| Primary completion | 2032-05-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-05-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ovarian Cancer
Interventions
- Drug: INCB123667
- Drug: Bevacizumab
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) by BICR
measured Up to approximately 5 years
Related
INCY · their whole pipeline · Ovarian Cancer readouts
INCY's other studiesmost recently updated first
- A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia Phase 3 · Recruiting
- Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease — · Recruiting
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) Phase 3 · Active, not recruiting
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa Phase 3 · Active, not recruiting
- A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation Phase 1 · Active, not recruiting
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed